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Introduction
============

D-dimer concentrations are highly sensitive for thrombus formation. Hence D-dimer tests are often used to rule-out venous thromboembolism (pulmonary embolism or deep vein thrombosis) in suspected patients with a non-high clinical probability. Patients with a high clinical probability do not require a D-dimer test. In these patients imaging examination is warranted to confirm or refute the diagnosis, irrespective of the D-dimer results (fig 1[](#fig1){ref-type="fig"}).[@ref1] [@ref2] [@ref3] However, D-dimer concentrations increase with age, which leads to a high proportion of older patients with D-dimer concentrations higher than conventional cut-off values (500 µg/L).[@ref4] [@ref5] This in turn leads to a low specificity (that is, more false positive results) of D-dimer testing in older patients suspected of having venous thromboembolism; the specificity is 49% to 67% for patients aged less than 50 years but in older old patients (≥80 years) between 0% and 18%.[@ref4] [@ref5] [@ref6] [@ref7] [@ref8] As imaging is indicated in patients suspected of having venous thromboembolism with a D-dimer concentration above the cut-off value,[@ref9] a high proportion of older patients with a non-high clinical probability undergo unnecessary diagnostic investigations. This can be burdensome, especially in older patients, and the yield of this imaging is relatively low (typically 20% or less of patients with clinically suspected venous thromboembolism are actually affected).[@ref10] [@ref11] As a result of a low specificity of D-dimer testing in older patients, some authors dissuade doctors from D-dimer testing in very old patients.[@ref4] [@ref8] [@ref12] Yet this would actually imply referring all suspected older patients for imaging, which is even less desirable.

![**Fig 1** Diagnostic investigations in patients with suspected venous thrombembolism. Adapted from Wells 2007,[@ref9] Le Gal et al 2006,[@ref40] and Wells et al 2001[@ref57]](schh009468.f1_default){#fig1}

Others have argued for increasing the D-dimer cut-off value in older patients to improve the specificity and thereby increase the number of patients in whom---based on a D-dimer level below the cut-off value---imaging could be avoided.[@ref4] [@ref6] [@ref13] [@ref14] [@ref15] An age adjusted D-dimer cut-off value that increases gradually with age especially showed a promising increase in specificity without substantial loss of safety.[@ref6] This age adjusted cut-off value was defined as age (years)×10 μg/L for patients aged over 50 years (for example, for a patient aged 78 years, the D-dimer concentration would be considered normal below 780 μg/L). The age adjusted cut-off value was derived from a cohort of secondary care patients with a non-high probability of pulmonary embolism. This cohort was subdivided into 10 year age groups and the optimal cut-off value was selected for each age group---that is, the cut-off value with a sensitivity of 100% and the highest accompanying specificity. This revealed an increase of the optimal cut-off value of approximately 100 μg/L per decade (10 μg/L per year). This age adjusted cut-off value was subsequently validated in secondary care patients with suspected pulmonary embolism,[@ref16] [@ref17] and in both primary and secondary care cohorts of patients with suspected deep vein thrombosis.[@ref18] [@ref19] However, higher cut-off values may also lead to an increased percentage of false negative cases (that is, missed cases of venous thromboembolism), which might make this strategy less safe.[@ref20] [@ref21] Since venous thromboembolism has a high short term mortality rate in older patients, doctors do not always get the chance to reconsider a missed diagnosis.[@ref22] [@ref23]

Controversy therefore remains on the utility of D-dimer testing (either using the conventional or higher cut-off values) to safely exclude venous thromboembolism in a substantial proportion of older patients. A formal systematic review increases the evidence base on this topic; a meta-analysis can provide more precise estimates of the accuracy of D-dimer testing among clinically relevant subgroups, whereby sources for interstudy heterogeneity can be considered.[@ref24] We conducted a systematic review and meta-analysis to assess the diagnostic value of D-dimer testing for excluding suspected venous thromboembolism in older patients, with a particular interest in whether increasing the threshold for test positivity using the proposed age adjusted manner is a safe and more efficient strategy than using the conventional cut-off value.

Methods
=======

Data sources and searches
-------------------------

On 12 June 2012 we systematically searched Embase and Medline for studies evaluating the diagnostic value of D-dimer tests in diagnosing venous thromboembolism. The search query combined synonyms for "D-dimer" with synonyms for "venous thromboembolism" and "elderly" (see supplementary appendix 1 for the search strategy).[@ref25] Duplicate articles were manually filtered using the "close match function" of Refworks 2.0.

Study selection
---------------

We included studies if they were original diagnostic studies and comprised a study population of consecutive patients with a clinical suspicion of venous thromboembolism, performed quantitative D-dimer testing using the age adjusted D-dimer cut-off value and the conventional cut-off value, and applied reference testing in all patients according to previously described methods.[@ref26]

No language restrictions were applied. To check cross referencing we used a previously published systematic review.[@ref1] We excluded studies carried out exclusively in populations with a high risk for thrombosis---defined as perioperative patients or patients with previous thrombosis, cancer, or coagulation disorders. When a study cohort was described by more than one article, we included only the paper best meeting the inclusion criteria. Two reviewers (HJS and NV) independently selected the first batch of articles and a third reviewer (GJG) was consulted by HJS to agree on the final selection and to resolve discrepancies between the first two reviewers.

Data extraction and quality assessment
--------------------------------------

We reviewed the included studies in duplicate and extracted the study design, setting, number of patients, prevalence of venous thromboembolism, personal characteristics of the study population, clinical decision rule used to classify patients in risk categories, and reference standard and D-dimer assay applied. Using extracted numbers of true and false positive and negative results according to the reference tests, we reconstructed 2×2 tables for the patients with a non-high clinical probability and stratified them by predefined age categories (≤50 years, 51-60 years, 61-70 years, 71-80 years, and \>80 years) and by the different D-dimer cut-off values (for the age category ≤50 years the conventional and age adjusted cut-off value are the same). If complete reconstruction of 2×2 tables using the desired age categories was not possible based on the data presented in the papers, we contacted the authors and requested to reanalyse their data, if needed, according to the predefined age class categories and to complete the cross tables for all age categories and for both the conventional and age adjusted D-dimer cut-off level.

We assessed risk of bias and applicability at study cohort level, using the revised tool for quality assessment of diagnostic accuracy studies (QUADAS-2). This is a validated tool for assessment of methodological quality and applicability of diagnostic accuracy studies.[@ref27] We appraised both the primary studies describing the included study cohorts and the publications included in this meta-analysis that were based on these cohorts.

Data synthesis and analysis
---------------------------

From the 2×2 tables we calculated the prevalence of venous thromboembolism and the D-dimer test sensitivity (the number of patients with venous thromboembolism and a D-dimer level above the tested cut-off value---that is, patients with true positive test results---divided by the total number of patients with venous thromboembolism) and specificity (the number of patients without venous thromboembolism and a D-dimer level below the tested cut-off level---that is, patients with true negative test results---divided by the total number of patients without venous thromboembolism).

To graphically display the sensitivity and specificity measurements at study level we used Review Manager 5 software from the Cochrane collaboration. For the main analyses we stratified the data by age category and D-dimer cut-off value. We used random effects bivariate regression models to meta-analyse the logit transformed sensitivity and specificity of D-dimer to obtain pooled estimates and 95% confidence intervals of these variables.[@ref28] [@ref29] The bivariate approach simultaneously models pairs of (logit transformed) sensitivity and specificity from studies, thereby incorporating any correlation that might exist between these measures. The model uses a random effects approach for both sensitivity and specificity to incorporate heterogeneity beyond chance as a result of remaining clinical and methodological differences between studies. We added covariates to the bivariate model to examine whether sensitivity and specificity were different for the following study characteristics: prevalence of venous thromboembolism within each study, the type of applied D-dimer assay, and whether the initial suspicion was deep vein thrombosis or pulmonary embolism in the included studies. We fitted the bivariate random effects models using the NLMIXED (non-linear mixed effect) procedure of SAS version 9.2 (SAS Institute, Cary, NC, USA).

For each age category and D-dimer cut-off level we constructed hypothetical classification tables including 1000 hypothetical patients per table. We calculated the total number of venous thromboembolism cases by multiplying 1000 with the estimated median prevalence of venous thromboembolism within the particular age category based on the studies included in this meta-analysis. We calculated the number of patients with true positive test results by multiplying the total number of hypothetical venous thromboembolism cases with the estimated sensitivity of the D-dimer test in the particular age category (or with the lower or upper 95% confidence interval border of the estimated sensitivity to extract a measure of uncertainty). To obtain the number of patients with true negative test results we multiplied the total number of hypothetical non-cases by the estimated specificity (or with the lower or upper limits of the 95% confidence interval of this estimate). To examine the influence of the prevalence on these numbers, we repeated these analyses using the minimum and maximum prevalence of venous thromboembolism within each age group based on this meta-analysis. These analyses were performed in Microsoft Office Excel version 2010.

Results
=======

Selection, characteristics, and quality of studies
--------------------------------------------------

Our search yielded 2696 unique publications (see flowchart in supplementary appendix 2). After we had screened the titles and abstracts, 307 publications were selected for full text review. Of these publications, 302 were excluded, mainly because they did not concern consecutive patients, applied no (quantitative) D-dimer test, or did not apply age adjusted D-dimer cut-off levels. Finally, five publications were included concerning a total of 22 608 patients of whom 12 630 had a non-high clinical probability of venous thromboembolism.[@ref6] [@ref16] [@ref17] [@ref18] [@ref19] All these publications concerned retrospective analyses on one or more cohorts of patients with suspected venous thromboembolism. One publication[@ref19] separately analysed and presented five different cohorts (Tan et al, unpublished),[@ref30] [@ref31] [@ref32] [@ref33]; two publications[@ref6] [@ref16] separately analysed and presented three different cohorts[@ref34] [@ref35] [@ref36] [@ref37] [@ref38] [@ref39] and the other two publications concerned one cohort each.[@ref17] [@ref18] Hence the five included publications concerned a total of 13 different study cohorts, which we considered as separate cohorts in this meta-analysis. All authors granted our requests to reanalyse their data and provided 2×2 tables for each predefined age category and both D-dimer cut-off levels.

Table 1[](#tbl1){ref-type="table"} summarises the characteristics of the included study cohorts. Seven cohorts concerned patients with suspected pulmonary embolism[@ref17] [@ref34] [@ref35] [@ref36] [@ref37] [@ref38] [@ref39] and the other six concerned patients with suspected deep vein thrombosis (Tan et al, unpublished).[@ref18] [@ref30] [@ref31] [@ref32] [@ref33] All studies analysed and presented only patients with non-high clinical probability scores on clinical decision rules as this is the indicated population for the application of D-dimer tests.[@ref3] [@ref9] To select these patients with a non-high clinical probability, either a revised Geneva score[@ref40] of ≤10 or a Wells score[@ref41] of ≤4 was applied in the pulmonary embolism cohorts; and for the deep vein thrombosis cohorts, a Wells score[@ref9] of either ≤2 or ≤1 was applied. In one study,[@ref31] a clinical probability of \<80% of deep vein thrombosis as estimated by the treating doctor---instead of a formal clinical decision rule---was used to select the patients with a non-high clinical probability.

###### 

 Characteristics of included study cohorts. Data were sorted according to primary suspicion of pulmonary embolism (PE) or deep vein thrombosis (DVT) and setting. All studies used D-dimer cut-off value of 500 ug/L and age×10 μg/L

  Reference\*                                          PE or DVT   No of patients (% male)   Mean age (SD)   Prevalence of VTE (%)   Setting                                                                          Reference test to rule out VTE                                                                                                                                                                                                                           D-dimer assay†                                    CDR used (cut-off)
  ---------------------------------------------------- ----------- ------------------------- --------------- ----------------------- -------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------- ---------------------------------------------------------------
  Douma 2010, derivation set^6\ 34^                    PE          1721 (41)                 61 (19)         24                      Hospital; outpatients presenting in emergency department or outpatient clinics   ((a) D-dimer \<500 μg/L; or (b) negative results from CUS and from HCT in patients with non-high CDR; or (c) normal VQ scan or normal pulmonary angiogram) and (3 month event free follow-up)                                                            ELFA                                              Wells^54^ (≤4)
  Douma 2010, validation set 2^6\ 36^                  PE          1819 (49)                 59 (19)         21                      Hospital; outpatients presenting in emergency department or outpatient clinics   ((a) Non-high CDR and D-dimer \<500 μg/L; or (b) negative HCT) and (3 month event free follow-up)                                                                                                                                                        ELFA                                              Revised Geneva score^40^ (≤10)
  Penaloza 2012, French cohort^16\ 38^                 PE          1529 (39)                 Not given       28                      Hospital; outpatients presenting in emergency department or outpatient clinics   ((a) D-dimer \<500 μg/L; or (b) normal pulmonary angiogram; or (c) negative VQ scan; or (d) negative HCT; or (e) low CDR and non-diagnostic VQ or HCT and negative CUS) and (3 month event free follow-up)                                               ELFA or quantitative latex agglutination assay    Revised Geneva score^40^ (≤10)
  Penaloza 2012, European cohort^16\ 37^               PE          1645 (42)                 59              18                      Hospital; outpatients presenting in emergency department or outpatient clinics   \(a\) Non-high CDR and D-dimer ELISA \<500 μg/L; or (b) non-high CDR and negative moderate sensitivity D-dimer test; or (c) low CDR and low probability VQ scan or negative computed tomography angiography; or (d) negative multidetector HCT           ELFA or quantitative latex agglutination assay    Revised Geneva score^40^ (≤10)
  Penaloza 2012, US cohort^16\ 42^                     PE          7940 (33)                 49              5.1                     Hospital; outpatients presenting in emergency department or outpatient clinics   ((a) D-dimer \<500 μg/L; or (b) normal VQ scan; or (c) non-diagnostic VQ scan and negative CUS and/or negative D-dimer (d) negative multidetector CT angiography) and (45 days follow-up)                                                                ELFA or quantitative latex agglutination assay    Revised Geneva score^40^ (≤10)
  Douma 2010, validation set 1^6\ 35^                  PE          3306 (43)                 53 (18)         20                      Hospital: inpatients and outpatients                                             ((a) Unlikely clinical probability and D-dimer ≤500 μg/L; or (b) negative HCT) and (3 month event free follow-up)                                                                                                                                        ELFA or quantitative latex agglutination assay    Wells^54^ (≤4)
  Van Es 2012^17\ 55^                                  PE          456 (46)                  65              27                      Hospital: inpatients and outpatients                                             ((a) Unlikely clinical probability and D-dimer ≤500 μg/L; or (b) negative HCT) and (3 month event free follow-up)                                                                                                                                        ELFA or quantitative latex agglutination assays   Wells^54^ (≤4)
  Schouten 2012‡^18\ 56^                               DVT         1374 (27)                 59 (17)         20                      Primary care patients                                                            Normal first and repeated CUS                                                                                                                                                                                                                            ELFA or quantitative latex agglutination assay    Wells^9^ (≤1)
  Douma 2012, cohort 1^7\ 19^                          DVT         812 (36)                  59 (17)         39                      Hospital; outpatients presenting in emergency department or outpatient clinics   ((a) Non-high CDR and D-dimer \<500 μg/L; or (b) negative results from first CUS and D-dimer \<500 μg/L; or (c) normal results from repeated CUS) and (3 month event free follow-up)                                                                     Quantitative latex agglutination assay            Wells^9^ (≤2)
  Douma 2012, cohort 2^19\ 31^                         DVT         474 (38)                  61 (19)         23                      Hospital; outpatients presenting in emergency department or outpatient clinics   ((a) D-dimer \<500 μg/L; or (b) normal CUS in combination with a non-high clinical probability; or (c) normal phlebography) and (3 month event free follow-up)                                                                                           ELFA                                              Clinical probability estimated by treating doctor^31^ (\<80%)
  Douma 2012, cohort 3^19\ 32^                         DVT         359 (41)                  66 (17)         23                      Hospital; outpatients presenting in emergency department or outpatient clinics   ((a) Low CDR and D-dimer \<500 μg/L and 3 month event free follow-up; or (b) normal CUS or impedance plethysmography. Patients with intermediate CDR and D-dimer \<500 μg/L imaged at treating doctor's discretion) and (3 month event free follow-up)   Quantitative latex agglutination assay            Wells^9^ (≤2)
  Douma 2012, cohort 4^19\ 33^                         DVT         556 (38)                  65 (16)         10                      Hospital; outpatients presenting in emergency department or outpatient clinics   ((a) Non-high CDR and normal D-dimer test and 3 month event free follow-up; or (b) normal repeated CUS) and (3 month event free follow-up)                                                                                                               Quantitative latex agglutination assay            Wells^9^ (≤2)
  Douma 2012, cohort 5 ^19^ (Tan et al, unpublished)   DVT         617 (52)                  58 (18)         37                      Hospital; outpatients presenting in emergency department or outpatient clinics   \(a\) Unlikely CDR and D-dimer \<500 μg/L; or (b) negative results from (first) leg venous CUS in combination with normal D-dimer \<500 μg/L; or (c) normal repeated CUS                                                                                 Quantitative latex agglutination assay            Wells^9^ (≤1)

PE=pulmonary embolism; DVT=deep vein thrombosis; VTE=venous thromboembolism; CDR=clinical decision rule; ELISA=enzyme linked immunosorbent assay; ELFA=enzyme linked fluorescent assay; CUS=compression ultrasonography of leg (if repeated; 6-8 days after initial presentation); HRCT=helical computed tomography of chest; VQ=ventilation perfusion.

\*Second reference refers to primary studies describing cohort.

†Classified according to Heim et al and Di Nisio et al.^2\ 48^

‡Study also presented data for cut-off value of 750 ug/L in patients aged \>60 years.^18^ These data were not included in this meta-analysis.

One study was performed in primary care,[@ref18] whereas all other cohorts concerned patients presenting at emergency departments or in outpatients clinics; in two studies, inpatients were also included.[@ref17] [@ref35]

Overall, the quality of the included study cohorts was good (see the results of QUADAS-2 in supplementary appendix 3). All but one cohort[@ref42] included prospectively collected data of consecutive patients with suspected venous thromboembolism. However, in 12 of the 13 study cohorts, three month event free follow-up (no signs or symptoms of recurrence) instead of imaging investigation was used as the reference test in patients with a negative D-dimer result and a non-high clinical probability, so not all patients underwent the same sequence of reference tests in these studies. Hence differential verification could have introduced bias. Furthermore, there were concerns about the applicability of the studies, as unstratified data for different applied D-dimer assays (enzyme linked fluorescent assays as well as quantitative latex assays) within one study cohort was presented for six of the 13 study cohorts.

Prevalence of venous thromboembolism and effect of age on specificity and sensitivity of D-dimer testing with a conventional cut-off value
------------------------------------------------------------------------------------------------------------------------------------------

The median prevalence of venous thromboembolism in patients not at high risk ranged from 12.3% in patients aged less than 50 years, to 21.5% in patients aged 71-80 (table 2[](#tbl2){ref-type="table"}). The pooled specificity of D-dimer testing decreased substantially with increasing age from 66.8% (95% confidence interval 61.3% to 72.0%) in patients aged less than 50 years to 14.7% (11.3% to 18.6%) in patients aged more than 80 years when the conventional cut-off value was applied (table 2). The pooled sensitivity hardly differed between the age groups.

###### 

 Pooled estimates of diagnostic accuracy of D-dimer testing in older patients with suspected venous thromboembolism and non-high clinical probability per age category and cut-off value in 13 study cohorts

  Age (years)   No of patients   Median (range) prevalence within studies (%)   Pooled sensitivity (95% CI)                         Pooled specificity (95% CI)                                                  
  ------------- ---------------- ---------------------------------------------- ----------------------------- --------------------- ----------------------------- -- --------------------- --------------------- ---------
  ≤50           5528\*           12.3 (3.09-28.6)                               97.6 (95.0 to 98.9)           NA†                   NA†                              66.8 (61.3 to 72.0)   NA†                   NA†
  51-60         2043\*           13.4 (5.00-33.3)                               100.0 (NA)                    99.4 (97.3 to 99.9)   0.97                             57.6 (51.4 to 63.6)   62.3 (56.2 to 68.0)   0.005
  61-70         1815             15.6 (6.58-26.2)                               99.0 (96.6 to 99.7)           97.3 (93.8 to 98.8)   0.14                             39.4 (33.5 to 45.6)   49.5 (43.2 to 55.8)   \<0.001
  71-80         1842             21.5 (6.78-34.5)                               98.7 (96.5 to 99.5)           97.3 (94.3 to 98.8)   0.20                             24.5 (20.0 to 29.7)   44.2 (38.0 to 50.5)   \<0.001
  \>80          1269             15.2 (5.88-26.9)                               99.6 (96.9 to 99.9)           97.0 (92.9 to 98.8)   0.06                             14.7 (11.3 to 18.6)   35.2 (29.4 to 41.5)   \<0.001

\*Additional data of cohort 5 of Douma 2012 study (Tan et al, unpublished), were not provided for these age categories (89 patients aged \<50 years and 44 patients aged 51-60 years).

†Age adjusted cut-off value (age×50 µg/L) does not apply (NA) to patients aged ≤50 years.

Performance of age adjusted D-dimer cut-off values
--------------------------------------------------

The use of the age adjusted D-dimer cut-off value (age×10 µg/L in patients aged \>50 years) still showed a decrease in specificity with increasing age, which was 35.2% (29.4% to 41.5%) in patients aged more than 80 years, but noticeably less pronounced compared with the application of the conventional cut-off value. The specificity of D-dimer testing by application of the age adjusted D-dimer cut-off value instead of the conventional cut-off value was higher in all age categories and was more than doubled in patients aged more than 80 years (table 2).

The use of age adjusted cut-off values instead of the conventional cut-off value was at the expense of a decrease in sensitivity (albeit small and not statistically significant), which stayed above 97% for both cut-off levels in all age categories.

Covariates
----------

The forest plot in supplementary appendix 4 depicts the sensitivity and specificity of D-dimer testing stratified by cohort, age group, and D-dimer cut-off level. We analysed the effect of covariates (the venous thromboembolism prevalence in each total cohort, applied D-dimer assays, and whether the patients were initially suspected of having pulmonary embolism or deep vein thrombosis) on the D-dimer sensitivity and specificity (table 3[](#tbl3){ref-type="table"}). We found no association between the sensitivity and specificity of D-dimer testing and the prevalence of venous thromboembolism in the study populations or whether patients were suspected of having either pulmonary embolism or deep vein thrombosis.

###### 

 Overall and covariate analysis for D-dimer testing stratified by use of conventional and age adjusted cut-off levels in patients with a non-high clinical probability of venous thromboembolism (all age categories except \<50 years)

  Analyses                                      No of cohorts   Sensitivity (95% CI)                         Specificity (95% CI)                          
  --------------------------------------------- --------------- ---------------------- --------------------- ---------------------- ---------------------- ---------------------
  Overall analyses: age-categories \>50 years   13              99.3 (98.4 to 99.7)    97.8 (95.9 to 98.9)                          36.1 (30.8 to 41.7)    48.8 (42.9 to 54.7)
  Prevalence in cohort (overall):                                                                                                                          
   \<23%                                        7               99.4 (98.2 to 99.8)    97.9 (95.3 to 99.1)                          37.5 (30.4 to 45.2)    49.9 (42.0 to 57.7)
   \>23%                                        6               99.1 (97.0 to 99.7)    97.7 (94.2 to 99.1)                          34.2 (26.7 to 42.5)    47.8 (39.1 to 56.5)
  P value                                       ---             0.64                   0.89                                         0.56                   0.73
  D-dimer assay:                                                                                                                                           
   Only ELFA                                    3               100 (NA)               99.6 (98.2 to 99.9)                          28.69 (20.6 to 38.5)   40.8 (30.8 to 51.7)
   Quantitative latex assay (and ELFA)†         10              98.7 (97.5 to 99.3)    96.4 (94.6 to 97.6)                          35.6 (32.9 to 42.5)    51.3 (45.2 to 57.4)
  P value                                       ---             0.97                   0.005                                        0.08                   0.10
  Clinical suspicion:                                                                                                                                      
   Pulmonary embolism                           7               99.2 (97.9 to 99.7)    97.5 (94.7 to 98.8)                          34.0 (27.7 to 40.9)    45.7 (38.5 to 53.1)
   Deep vein thrombosis                         6               99.8 (97.8 to 99.97)   99.3 (96.6 to 99.8)                          36.0 (34.0 to 38.0)    48.0 (45.8 to 50.2)
  P value                                       ---             0.31                   0.15                                         0.58                   0.55

ELFA=enzyme linked fluorescent assay; NA=not applicable.

\*Covariate analysis for setting was not possible as only one study was performed in primary care.

†This stratum contains studies wherein quantitative latex agglutination assays were used, or latex agglutination assays indifferently with ELFA assays.

D-dimer testing revealed a higher sensitivity and a trend towards lower specificity in the three cohorts in which only enzyme linked fluorescent assays were applied, compared with the cohorts in which quantitative latex assays were also used. Besides, the enzyme linked fluorescent assays showed less decrease in sensitivity by application of the age adjusted cut-off value instead of the conventional cut-off.

Hypothetical cohort
-------------------

Based on hypothetical cohorts of 1000 patients for each age category, we calculated the numbers of extra patients in whom imaging examination would, correctly or wrongly, be avoided by using the age adjusted instead of the conventional D-dimer cut-off value (table 4[](#tbl4){ref-type="table"}). This would result in a correct exclusion of venous thromboembolism in 40 (95% confidence interval 38 to 41), 85 (81 to 86), 155 (141 to 164), and 175 (153 to 194) extra patients at the expense of 1 (0 to 4) extra missed cases for those aged 51-60 years, 2 (2 to 5) for those aged 61-70 years, 3 (2 to 4), for those aged 71-80 years, and 4 (2 to 6) for those aged more than 80 years. D-dimer testing would rule out venous thromboembolism in 124 per 1000 non-high risk patients aged more than 80 years if the conventional cut-off value would be applied, whereas the application of the age adjusted D-dimer cut-off value results in exclusion of venous thromboembolism in 303 per 1000 of these patients. The positive predictive value was 21.2% (95% confidence interval 19.1% to 23.2%) in patients aged more than 80 years and 29.1% (25.3% to 33.1%) in patients aged 50 years or less. To examine the influence of the prevalence on this figure we also compared these numbers for the lowest and highest prevalence of venous thromboembolism of the non-high risk patients within each age category of the studies in this meta-analysis (fig 2[](#fig2){ref-type="fig"}). The relative merit of application of the age adjusted cut-off value instead of the conventional cut-off value was higher in the case of a low prevalence (44-194 correct *v* 0-2 falsely excluded cases) compared with a high prevalence (31-150 correctly *v* 2-7 falsely excluded cases) (see fig 2 and supplementary appendix 5).

###### 

 Classification table for 1000 hypothetical patients based on median prevalence of venous thromboembolism (VTE) in each age subgroup\* and on pooled estimates of sensitivity and specificity

  Variables                                        Age (years)                                                                                                   
  ------------------------------------------------ ------------- ------ ------- ------- ------ ------- ------ ------ ------- ------ ------ ------- ------ ------ -------
  Conventional cut-off value                       VTE+          VTE-   Total   VTE+    VTE-   Total   VTE+   VTE-   Total   VTE+   VTE-   Total   VTE+   VTE-   Total
  D-dimer high                                     120           291    411     134     367    501     154    512    666     212    593    805     151    724    876
  D-dimer low                                      3             586    589     0       499    499     2      332    334     3      192    195     1      124    124
  Total                                            123           877    1000    134     866    1000    156    844    1000    215    785    1000    152    848    1000
  Sensitivity/specificity                          97.6          66.8   ---     100.0   57.6   ---     99.0   39.4   ---     98.7   24.5   ---     99.6   14.6   ---
  Age adjusted cut-off value                       ---           ---    ---     VTE+    VTE-   Total   VTE+   VTE-   Total   VTE+   VTE-   Total   VTE+   VTE-   Total
  D-dimer high                                     ---           ---    ---     133     327    460     152    427    578     209    438    647     147    550    697
  D-dimer low                                      ---           ---    ---     1       539    540     4      417    422     6      347    353     5      298    303
  Total                                            ---           ---    ---     134     866    1000    156    844    1000    215    785    1000    152    848    1000
  Sensitivity/specificity                          ---           ---    ---     99.4    62.3   ---     97.3   49.5   ---     97.3   44.2   ---     97.0   35.2   ---
  No of avoided unnecessary imaging examinations   ---           ---    ---     ---     40     ---     ---    85     ---     ---    155    ---     ---    175    ---
  Additional No of cases missed                    ---           ---    ---     1       ---    ---     2      ---    ---     3      ---    ---     4      ---    ---

\*12.3% in patients aged ≤50, 13.4% in patients aged 51-60, 15.6% in patients aged 61-70, 21.5% in patients aged 71-80, and 15.2% in patients aged \>80 years.

![**Fig 2** Number of extra patients per 1000 patients with non-high clinical probability in whom venous thromboembolism would be correctly or falsely excluded by application of age adjusted D-dimer cut-off values instead of conventional cut-off values](schh009468.f2_default){#fig2}

Discussion
==========

We performed a systematic review and meta-analysis on the diagnostic value of D-dimer testing to exclude venous thromboembolism in older patients aged 50 or more years. Generally, in combination with a non-high clinical probability, D-dimer testing is used as a rule-out test in patients with suspected venous thromboembolism. Using such a rule-out approach, unnecessary burdensome and more costly imaging can be avoided in about 1 in 3 patients.[@ref1] [@ref2] [@ref30] [@ref33] [@ref34] [@ref35] However, this proportion of patients in whom imaging can be safely withheld by using D-dimer testing seemed to be low (around 10%) in the eldest patients (\>80 years).[@ref4] [@ref8] [@ref12] This has led to controversy over the diagnostic value of D-dimer testing in older old patients (\>80 years) with clinically suspected venous thromboembolism. In particular old, fragile patients, who would benefit if an unnecessary referral to a radiology department could be safely avoided.[@ref43] In fact, this was the main reason for the development of age adjusted cut-off values for D-dimer testing[@ref6] and thereby the reason for this aggregated meta-analysis.

Indeed we found a sharp decrease in the specificity of D-dimer testing to rule out venous thromboembolism in older patients with a non-high clinical probability using the conventional D-dimer cut-off value, although the sensitivities of D-dimer testing were high across all age categories. The proportion of patients with a non-high clinical probability in whom D-dimer testing could exclude venous thromboembolism was only 12.4% in those aged more than 80 years. This finding underlines the arguments of several authors that D-dimer testing in this conventional way is of limited value in the eldest patients.[@ref4] [@ref8] [@ref12] Yet the application of the age adjusted D-dimer cut-off value[@ref6] would result in the exclusion of venous thromboembolism in almost 1 out of 3 (30.3%) of the eldest patients (\>80 years), while the sensitivity stayed above 97% in all age categories. This would lead to one identified and treated patient for every five patients undergoing imaging examinations in the eldest patients, or in other words a positive predictive value of 21.1%. This positive predictive value of D-dimer testing in the eldest patients is almost comparable to the positive predictive value of 29.2% in the youngest patients (\<50 years, cut-off value of 500 µg/L). The small number of missed cases from applying the age adjusted cut-off value instead of the conventional cut-off (1 to 4 per 1000 ) is largely outnumbered by the large number of patients in whom imaging would be avoided (303 to 540 per 1000). Moreover, this number of missed cases from using the age adjusted cut-off value is comparable to the failure rate in the youngest age category (≤50 years) in whom 3 per 1000 patients would be missed if D-dimer testing using conventional cut-off levels was used. Even in case of a high prevalence of venous thromboembolism (when the relative merit of application of the age adjusted cut-off value is lowest) the additional number of patients missed (2 to 7 per 1000) would be outweighed by the number of avoided unnecessary imaging examinations (31 to 150 per 1000).

Currently, broadly available imaging techniques for the detection of venous thromboembolism have replaced burdensome and time consuming techniques bringing about high radiation exposure (repeated two point compression ultrasonography replaced venography for the detection of deep vein thrombosis, and contrast enhanced computed tomography of the pulmonary arteries replaced pulmonary angiography for pulmonary embolism).[@ref35] [@ref44] Still, the burden and risks of imaging, such as attending a hospital, extension of hospital stay, waiting at a radiology department , are of particular concern for old patients.[@ref43] Moreover, contrast enhanced computed tomography of the pulmonary arteries is associated with a 14% risk of nephropathy, which might be even higher in older patients in whom renal impairment is more common.[@ref45] Therefore it would (notably for older patients) be beneficial to safely withhold imaging investigations based on negative D-dimer test results.

Strengths and limitations of this review
----------------------------------------

This is the first systematic review and meta-analysis on the diagnostic utility of D-dimer testing in older patients. We were able to include 13 large cohorts involving over 12 000 patients wherein both the conventional adjusted and the age adjusted cut-off values were studied in different age categories. However, the included publications were from only three research groups. Our search yielded another 107 publications in which the diagnostic accuracy of quantitative D-dimer testing had been examined in consecutive patients, but as this was not done in an age adjusted manner these publications were not included in our meta-analysis. Yet given the robustness, precision, and consistency of our results over the 13 included cohorts, we expect that the addition of more studies to the meta-analysis would not have changed our inferences. Moreover, funnel plots of estimates of the effect size (differences in logit specificities within studies as a result of the application of the different cut-off levels) against the study size, gave (although based on a small number of studies) no indication for publication bias (analysis not presented).

Other strategies to adjust the D-dimer cut-off value to exclude venous thromboembolism in older patients have been suggested---for example, a fixed cut-off of 750 µg/L in all patients aged over 60 or 70 years.[@ref14] [@ref21] [@ref46] [@ref47] Owing to the heterogeneity of the applied D-dimer assays, methodology, and categorization of age (for example, \>60 or \>70 years instead of 61-70 years, 71-80 years, and \>80 years), we were unable to provide pooled estimates of the studies that analysed alternative D-dimer cut-off levels. This hampered the comparison of the different adjusted D-dimer cut-off values.

We also found some heterogeneity in the sensitivity and specificity of D-dimer tests among the studies, partly explained by the application of different assays. Our covariate analysis suggests that the application of age adjusted instead of conventional cut-off values was most favourable in the cohorts in which enzyme linked fluorescent assays were only applied, as the high sensitivity remained constant in these cohorts. These findings are consistent with previous studies: enzyme linked fluorescent assays turned out to have a higher sensitivity at the expense of a lower specificity compared with second generation latex assays.[@ref2] [@ref48] However, as a result of between study variation of covariates and their potential multicollinearity (linear relation between explaining variables), we are unable to draw firm conclusions on the differences between various D-dimer assays based on our current meta-analysis.

Another limitation might be that we included studies both with populations suspected of having pulmonary embolism and with populations suspected of having deep vein thrombosis, and primary as well as secondary care patients, which might have introduced some extra between study variation. Furthermore, there was a variation in the prevalence of venous thromboembolism in the included cohorts, ranging from 5.1% to 39%. However, although previous studies revealed an association between the prevalence of venous thromboembolism and the diagnostic accuracy of D-dimer testing,[@ref49] our covariate analysis did not show such an association. Moreover, there was a fair similarity of study design and patient selection over the included cohorts; in all studies only patients with a non-high clinical probability were selected. Therefore we assumed that the conditions for pooling were met.

Finally, the reference standards used to diagnose or exclude venous thromboembolism differed between the included studies. In all but one study[@ref18] differential verification was of concern; in these studies venous thromboembolism was excluded without confirmation by imaging in patients with a negative D-dimer test result and without recurrence of symptoms during follow-up. Hence the false negative cases from using the conventional cut-off value were patients presenting with worsening or recurrence of their symptoms within 45 days or three months, leading to further examinations and the detection of venous thromboembolism. Although this is common practice, this could have introduced small overestimations of the diagnostic accuracy of the D-dimer test, as small thrombi may have been missed in these patients.

Conclusions and implications for further research
-------------------------------------------------

D-dimer testing has limited utility in older patients when the conventional cut-off value is applied. The application of the age adjusted cut-off value combined with a non-high clinical probability greatly increases the utility of a D-dimer test for the exclusion of venous thromboembolism in older patients, while hardly affecting the sensitivity. D-dimer levels below the age adjusted cut-off value correctly avoided imaging examinations in 30% to 54% of older patients with a non-high probability. This meta-analysis shows the robustness of our findings for patients with suspected deep vein thrombosis or pulmonary embolism, as well as for different age groups, D-dimer assays, and prevalence of venous thromboembolism.

Given that the age adjusted cut-off level could be easily implemented in routine laboratory practice it may have an immediate impact in clinical practice and serve the needs of older patients with a non-high clinical probability of venous thromboembolism by sparing a substantial proportion the burden of imaging investigations. Our results are not, however, applicable to patients with a high clinical probability of venous thromboembolism as additional imaging examination is warranted in these patients, irrespective of the D-dimer test results. Furthermore, since this strategy has only been confirmed in retrospective analyses, it could be argued that a formal cost effectiveness modeling study[@ref50] [@ref51] or even a prospective impact study[@ref52] [@ref53] is needed to further confirm the cost effectiveness and ease of use and acceptability of this diagnostic strategy in daily patient care before its implementation in clinical practice.

### What is already known on this topic

1.  A negative D-dimer test can rule out venous thromboembolism in patients with a non-high clinical probability

2.  Since D-dimer levels increase with age, the proportion of false positive D-dimer test results for venous thromboembolism using conventional cut-off values (500 µg/L) increases in older patients and the specificity decreases

3.  Age adjusted D-dimer cut-off values (age×10 µg/L) have therefore been introduced

### What this study adds

1.  This systematic review and meta-analysis established a poor specificity (around 15%) of D-dimer testing with the conventional cut-off value in the eldest patients (\>80 years)

2.  The application of the age adjusted cut-off value increased the specificity of the D-dimer test to 35% in the eldest patients, while hardly affecting the sensitivity

3.  Use of age adjusted D-dimer cut-off values would result in imaging examinations being correctly avoided in 30-54% of older patients with a non-high clinical probability of venous thromboembolism

We thank Nienke A F Verheijden for double checking our search and data extraction; Bianca Kramer for her help in the design of the search syntax; and Andrea Penaloza, Josien van Es, Gregoire Le Gal, Roger Schutgens, Cristina Legnani, Shanon Bates, Menno Huisman, and Melanie Tan for providing additional data.

Contributors: HJS, GJG, and JBR participated in the study concept and design, interpretation of data, and drafting of the manuscript. HJS, GJG, and NV performed the search and data extraction. RAD acquired additional data and critically revised the manuscript. HLK, KJMJ, and NPAZ critically revised the manuscript. JBR and NPAZ participated in analysis of the data. JBR, KGMM, and JJMD provided critical revision of the manuscript and study supervision. All authors had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors participated in the revision and final approval of the manuscript.

Funding: This study was supported by the Netherlands Organization for Scientific Research (ZonMw project No 9120-8004, 918-10-615, and 17088-2502). The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: All authors have completed the ICMJE uniform disclosure form at [www.icmje.org/coi_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) (available on request from the corresponding author) and declare: all authors had financial support from the Netherlands Organization for Scientific Research (ZonMw project No 17088-2502, 917-46-360, and 945-04-009) for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: Not required.

Data sharing: No additional data available.

Cite this as: *BMJ* 2013;346:f2492
